Aquilo Capital Management, LLC
SAN FRANCISCO, CA · CIK 1591986 · 13F filing filed 2023-02-14
No investment adviser registration (Form ADV) found for this filer. It may be a parent company whose subsidiaries are the registered advisers, a bank or insurer, or a manager based outside the US.
- Legal entityAQUILO CAPITAL MANAGEMENT, LLC (US)
- Others nearbySan Francisco, CA
$224.7m
reported value
-5.5% vs Q3 2022
12positions
93.8%in top 10
0 new
6 added
5 reduced
2 sold out
vs Q3 2022
Options: 0 call positions (— notional), 1 put positions ($41.5m notional) – listed below, not included above.
Holdings, Q4 2022
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| ARROWHEAD PHARMACEUTICALS IN ARWR | $44.8m19.92% | Reduced -115.0k |
| BLUEPRINT MEDICINES CORP BPMC | $25.5m11.34% | Added +57.5k |
| ARVINAS INC ARVN | $23.1m10.26% | Added +2.2k |
| MERUS N V MRUS | $22.2m9.86% | Reduced -75.0k |
| REGENXBIO INC RGNX | $20.4m9.06% | Reduced -70.0k |
| SILENCE THERAPEUTICS PLC SLN | $19.6m8.71% | Added +21.0k |
| KYMERA THERAPEUTICS INC KYMR | $15.7m6.99% | Added +299.2k |
| AMRYT PHARMA PLC SPONSORED ADS | $15.3m6.82% | Added +100.0k |
| UNIQURE NV QURE | $14.2m6.30% | Reduced -216.6k |
| GENMAB A/S GMAB | $10.3m4.58% | Reduced -2.0k |
| ARGENX SE ARGX | $9.1m4.05% | Unchanged |
| PIERIS PHARMACEUTICALS INC COM | $4.7m2.11% | Added +516.6k |
Sold out since Q3 2022
| Security | Value then |
|---|---|
| SPERO THERAPEUTICS INC SPRO | $6.8m3.4m shares |
| 4D MOLECULAR THERAPEUTICS IN FDMT | $29.0k3.6k shares |
Options (notional value)
| Underlying | Notional | Change |
|---|---|---|
| SPDR SER TR XBI · Put | $41.5m500.0k shares | Unchanged |